Study finds GLP-1 body-composition effects
- Researchers in the International Journal of Obesity reported April 25 that glucagon-like peptide-1 drugs cut weight in adults with overweight or obesity mostly by reducing fat mass, not lean tissue. - The meta-analysis pooled 36 studies, including 24 in quantitative synthesis, and found body weight fell about 9% at three months, 5% at six months, and 4% at 12 months. - The findings sharpen a live clinical question about “quality” weight loss as use of semaglutide and tirzepatide expands, alongside advice to pair treatment with nutrition and exercise. (nature.com)
Glucagon-like peptide-1 drugs help people lose weight by making them eat less, but the key question is what tissue they lose. A new meta-analysis says most of that loss is fat, with lean mass relatively preserved. (nature.com) The paper, published April 25 in the International Journal of Obesity, reviewed adults with overweight or obesity, with and without type 2 diabetes. The authors included 36 studies in the systematic review and 24 in the quantitative meta-analysis. (nature.com) (pubmed.ncbi.nlm.nih.gov) Across the pooled trials, body weight fell about 9% at three months, 5% at six months, and 4% at 12 months. Fat mass and visceral adipose tissue, the deeper abdominal fat linked to cardiometabolic risk, dropped the most. (nature.com) (pubmed.ncbi.nlm.nih.gov) Lean mass is everything in the body that is not fat, including muscle, organs, bone, and body water. That matters because headlines about “muscle loss” can overstate what body-composition scans are actually measuring. (dom-pubs.onlinelibrary.wiley.com) The new review found reductions in lean body mass were modest overall, while semaglutide, liraglutide, and exenatide showed comparable effects at six months. The authors said the pattern supports “quality” weight loss rather than indiscriminate tissue loss. (nature.com) (pubmed.ncbi.nlm.nih.gov) That does not end the debate over muscle. A 2024 review in Diabetes, Obesity and Metabolism said lean-mass losses reported in GLP-1 studies vary widely, from roughly 15% to 60% of total weight lost, depending on the population, drug, and measurement method. (dom-pubs.onlinelibrary.wiley.com) That review also noted that smaller lean-mass readings do not automatically mean weaker muscle. Imaging studies suggest some changes may reflect expected adaptation during weight loss, alongside improvements in insulin sensitivity and lower fat infiltration in muscle. (dom-pubs.onlinelibrary.wiley.com) The new meta-analysis ends with a practical point: drug choice may matter, and treatment should be paired with nutrition and exercise. As GLP-1 use spreads, the question is shifting from how many pounds come off to how much fat comes off with them. (nature.com)
